Managing of screening-detected sub-solid nodules—a European perspective

Research output: Contribution to journalReviewResearchpeer-review

Standard

Managing of screening-detected sub-solid nodules—a European perspective. / Ricciardi, Sara; Booton, Richard ; Petersen, René Horsleben; Infante, Maurizio V; Scarci, Marco; Veronesi, Giulia; Cardillo, Giuseppe.

In: Translational Lung Cancer Research, Vol. 10, No. 5, 2021, p. 2368-2377.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Ricciardi, S, Booton, R, Petersen, RH, Infante, MV, Scarci, M, Veronesi, G & Cardillo, G 2021, 'Managing of screening-detected sub-solid nodules—a European perspective', Translational Lung Cancer Research, vol. 10, no. 5, pp. 2368-2377. https://doi.org/10.21037/tlcr.2020.03.37

APA

Ricciardi, S., Booton, R., Petersen, R. H., Infante, M. V., Scarci, M., Veronesi, G., & Cardillo, G. (2021). Managing of screening-detected sub-solid nodules—a European perspective. Translational Lung Cancer Research, 10(5), 2368-2377. https://doi.org/10.21037/tlcr.2020.03.37

Vancouver

Ricciardi S, Booton R, Petersen RH, Infante MV, Scarci M, Veronesi G et al. Managing of screening-detected sub-solid nodules—a European perspective. Translational Lung Cancer Research. 2021;10(5):2368-2377. https://doi.org/10.21037/tlcr.2020.03.37

Author

Ricciardi, Sara ; Booton, Richard ; Petersen, René Horsleben ; Infante, Maurizio V ; Scarci, Marco ; Veronesi, Giulia ; Cardillo, Giuseppe. / Managing of screening-detected sub-solid nodules—a European perspective. In: Translational Lung Cancer Research. 2021 ; Vol. 10, No. 5. pp. 2368-2377.

Bibtex

@article{e773ffa7e2c54162807140fa6c882f4a,
title = "Managing of screening-detected sub-solid nodules—a European perspective",
abstract = " Since the National Lung Screening Trial in 2011 showed a 20% reduction in lung cancermortality using annual low-dose computed tomography (LDCT), several randomised controlled trials and studies have been started in Europe. These include the Italian lung study (ITALUNG), the Dutch-Belgian lung cancer screening trial (NELSON), the UK lung cancer screening trial (UKLS), the Detection and screening of early lung cancer with novel imaging technology (DANTE), the Danish lung cancer screening trial (DLCST), the German lung cancer screening intervention trial (LUSI), the Multicentric Italian lung detection trial (MILD) and the CT screening for lung cancer study (COSMOS). As a result of the increasing number of screening trials and the growing utilization of LDCT, the high detection of subsolid nodules is an increasingly important clinical problem. In the last few years, several guidelines have been published and providing guidance on the optimal management of subsolid nodules, but many controversies still exist. Follow-up imaging plays an important role in clinical assessment and subsequent management of this particular type of lung nodules, since they can be transient inflammatory lesions, and if persistentthey can be both benign lesions or lung cancers of variable clinical behaviour. However, the vast majority of subsolid nodules retain an indolent course over many years. The aim of this review is to present a European perspective in management of screening detected subsolid nodules ",
author = "Sara Ricciardi and Richard Booton and Petersen, {Ren{\'e} Horsleben} and Infante, {Maurizio V} and Marco Scarci and Giulia Veronesi and Giuseppe Cardillo",
year = "2021",
doi = "10.21037/tlcr.2020.03.37",
language = "English",
volume = "10",
pages = "2368--2377",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "5",

}

RIS

TY - JOUR

T1 - Managing of screening-detected sub-solid nodules—a European perspective

AU - Ricciardi, Sara

AU - Booton, Richard

AU - Petersen, René Horsleben

AU - Infante, Maurizio V

AU - Scarci, Marco

AU - Veronesi, Giulia

AU - Cardillo, Giuseppe

PY - 2021

Y1 - 2021

N2 - Since the National Lung Screening Trial in 2011 showed a 20% reduction in lung cancermortality using annual low-dose computed tomography (LDCT), several randomised controlled trials and studies have been started in Europe. These include the Italian lung study (ITALUNG), the Dutch-Belgian lung cancer screening trial (NELSON), the UK lung cancer screening trial (UKLS), the Detection and screening of early lung cancer with novel imaging technology (DANTE), the Danish lung cancer screening trial (DLCST), the German lung cancer screening intervention trial (LUSI), the Multicentric Italian lung detection trial (MILD) and the CT screening for lung cancer study (COSMOS). As a result of the increasing number of screening trials and the growing utilization of LDCT, the high detection of subsolid nodules is an increasingly important clinical problem. In the last few years, several guidelines have been published and providing guidance on the optimal management of subsolid nodules, but many controversies still exist. Follow-up imaging plays an important role in clinical assessment and subsequent management of this particular type of lung nodules, since they can be transient inflammatory lesions, and if persistentthey can be both benign lesions or lung cancers of variable clinical behaviour. However, the vast majority of subsolid nodules retain an indolent course over many years. The aim of this review is to present a European perspective in management of screening detected subsolid nodules

AB - Since the National Lung Screening Trial in 2011 showed a 20% reduction in lung cancermortality using annual low-dose computed tomography (LDCT), several randomised controlled trials and studies have been started in Europe. These include the Italian lung study (ITALUNG), the Dutch-Belgian lung cancer screening trial (NELSON), the UK lung cancer screening trial (UKLS), the Detection and screening of early lung cancer with novel imaging technology (DANTE), the Danish lung cancer screening trial (DLCST), the German lung cancer screening intervention trial (LUSI), the Multicentric Italian lung detection trial (MILD) and the CT screening for lung cancer study (COSMOS). As a result of the increasing number of screening trials and the growing utilization of LDCT, the high detection of subsolid nodules is an increasingly important clinical problem. In the last few years, several guidelines have been published and providing guidance on the optimal management of subsolid nodules, but many controversies still exist. Follow-up imaging plays an important role in clinical assessment and subsequent management of this particular type of lung nodules, since they can be transient inflammatory lesions, and if persistentthey can be both benign lesions or lung cancers of variable clinical behaviour. However, the vast majority of subsolid nodules retain an indolent course over many years. The aim of this review is to present a European perspective in management of screening detected subsolid nodules

U2 - 10.21037/tlcr.2020.03.37

DO - 10.21037/tlcr.2020.03.37

M3 - Review

C2 - 34164284

VL - 10

SP - 2368

EP - 2377

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 5

ER -

ID: 257875081